公开(公告)号：US20160052890A1

公开(公告)日：2016-02-25

申请号：US14786345

申请日：2014-04-22

申请人： THE GENERAL HOSPITAL CORPORATION

发明人： Robert Zahler ,  Ronald Thure Wester ,  Steven Joseph Brickner

IPC分类号： C07D235/28 ,  C07D413/12 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04 ,  C07D235/26 ,  C07D403/04 ,  C07D405/12 ,  C07D263/58 ,  C07D417/12 ,  C07D235/16

CPC分类号： C07D235/28 ,  C07D235/16 ,  C07D235/26 ,  C07D235/30 ,  C07D263/58 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

摘要： The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

摘要翻译： 本公开提供了可用于治疗慢性和急性细菌感染的化合物和药物组合物。 某些化合物是通式VIII的化合物和盐本公开某些化合物是MvfR抑制剂。 MvfR抑制剂减少抗生素耐受性细菌菌株的形成，并且可用于治疗革兰氏阴性细菌感染并降低铜绿假单胞菌的毒力。 本发明还提供了治疗患者细菌感染的方法，包括铜绿假单胞菌感染。

公开(公告)号：US09643933B2

公开(公告)日：2017-05-09

申请号：US14786345

申请日：2014-04-22

申请人： The General Hospital Corporation

发明人： Robert Zahler ,  Ronald Thure Wester ,  Steven Joseph Brickner

IPC分类号： C07D235/08 ,  C07D235/28 ,  C07D401/12 ,  C07D403/12 ,  C07D235/16 ,  C07D235/26 ,  C07D235/30 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04 ,  C07D263/58 ,  C07D417/12

CPC分类号： C07D235/28 ,  C07D235/16 ,  C07D235/26 ,  C07D235/30 ,  C07D263/58 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

摘要： The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.